Terns Pharmaceuticals Inc
TERN
Market Cap$294.81M
Close$
$1.11
76.9% downside
Current Fair Value
76.9% downsideOvervalued by 76.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $294.81 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 0.0 |
| Outstanding Shares | 64,651,693 |
| Avg 30 Day Volume | 946,188 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Terns Pharmaceuticals Inc
30 employeesTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chr...